We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

11 hedge funds and large institutions have $196K invested in Northwest Biotherapeutics, Inc. Common stock in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

6% less capital invested

Capital invested by funds: $209K → $196K (-$12.3K)

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$7.23K
2
SL
Sentinus LLC
Illinois
+$3.55K

Top Sellers

Rank Fund Capital Flow
1
MCM
MAI Capital Management
Ohio
-$6.4K
2
LDB
Lee, Danner & Bass
Tennessee
-$6K
3
WJWM
Williams Jones Wealth Management
New York
-$2.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$134K +$7.23K +26,305 +6%
VWA
2
VSM Wealth Advisory
Maryland
$18K +$18K +65,574 New
OCG
3
Opus Capital Group
Ohio
$17K – – –
WJWM
4
Williams Jones Wealth Management
New York
$7.42K -$2.2K -8,000 -23%
EFG
5
Ethos Financial Group
Pennsylvania
$6.51K – – –
AA
6
AlphaMark Advisors
Kentucky
$4K – – –
SL
7
Sentinus LLC
Illinois
$3.55K +$3.55K +12,925 New
AMG
8
Advisors Management Group
Wisconsin
$3K – – –
KA
9
KLCM Advisors
Wisconsin
$2.75K – – –
LDB
10
Lee, Danner & Bass
Tennessee
– -$6K -20,000 Closed
MCM
11
MAI Capital Management
Ohio
– -$6.4K -20,000 Closed

NWBO Hedge Fund Activity: Q4 2024 in Review

11 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2024, worth a combined $196K — down 5.9% from $209K a quarter earlier.

Fund positioning in NWBO was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Moloney Securities Asset Management, adding an estimated $7.23K. The largest seller was MAI Capital Management, exiting entirely with an estimated $6.4K sold.

  • 11 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $196K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2024, down 5.9% quarter-over-quarter.
  • 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2024 and 2 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2024 was Moloney Securities Asset Management, an estimated $7.23K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2024 was MAI Capital Management, an estimated $6.4K sold.

Based on aggregated 13F filings for Q4 2024.